Bacteremia due to Leuconostoc species: A 13-year single-center case series

Enferm Infecc Microbiol Clin (Engl Ed). 2024 Mar;42(3):149-151. doi: 10.1016/j.eimce.2023.01.007. Epub 2023 Apr 21.

Abstract

Introduction: Leuconostoc spp. are facultatively anaerobic Gram-positive cocci involved in cases of hospital-acquired bacteremia, mainly in immunocompromised hosts. The available data is scarce due to its uncommon presentation.

Methods: We describe all the episodes of Leuconostoc spp. bacteremia in a third level hospital in a 13-year period (2008-2021).

Results: Four cases of clinically relevant bacteremia were detected. All cases were categorized as catheter-related. The following risk factors were found: previous glycopeptide therapy (75%), use of parenteral nutrition (100%) and cancer (75%). All isolates showed susceptibility to beta-lactams. Catheter removal was performed and wide spectrum antimicrobials were administered, with clinical response in all cases except one.

Discussion: Apart from cancer and glycopeptide exposure, disruption of skin barrier and gastrointestinal conditions were identified as risk factors, as it was concordantly underlined in other case series. Susceptibility to beta-lactams is usually maintained. Catheter removal and administration of an active antibacterial therapy seem to be the best approach for Leuconostoc spp. catheter-related bacteremia.

Keywords: Bacteremia; Bacteriemia; Desenlace; Infección; Infection; Leuconostoc spp; Outcome; Tratamiento; Treatment.

Publication types

  • Case Reports

MeSH terms

  • Bacteremia* / microbiology
  • Catheters, Indwelling / microbiology
  • Glycopeptides / adverse effects
  • Gram-Positive Bacterial Infections* / diagnosis
  • Gram-Positive Bacterial Infections* / drug therapy
  • Gram-Positive Bacterial Infections* / etiology
  • Humans
  • Leuconostoc
  • Neoplasms* / complications
  • beta-Lactams / pharmacology

Substances

  • beta-Lactams
  • Glycopeptides